止血診断薬の世界市場：市場規模・シェア・動向分析 (製品別・検査別・最終用途別・地域別)、セグメント別予測 (2025年～2030年)

止血診断薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の止血診断薬市場規模は2030年までに14億9,000万米ドルに達し、2025年から2030年までのCAGRは4.5％を記録すると予測されています。

同市場は、世界の高齢者人口の増加、診断技術の進歩、出血・凝固障害に対する意識の高まり、慢性疾患の有病率の上昇など、さまざまな要因によって大きな成長を示す可能性が高いです。

市場促進要因のひとつは、高齢者人口の増加です。高齢化に伴い、静脈血栓塞栓症、心房細動、その他の心血管系疾患など、止血に影響を及ぼす疾患の開発可能性が高まる。高齢者はまた、過剰出血や血栓形成などの合併症を避けるために凝固レベルの正確なモニタリングを必要とする手術を受ける可能性も高くなります。このような人口動向は、血液凝固や出血のリスクを評価できる診断ツールの需要を押し上げています。

製品開発における技術進歩も市場発展に寄与しています。ポイントオブケア機器のような高度で正確な診断分析装置の開発により、医療提供者はさまざまな医療現場で凝固パラメータを迅速にモニタリングすることが容易になりました。このような進歩により、止血障害の診断のスピードと効率が向上しており、これは特に救急医療や救命医療の現場で重要です。

さらに、自動分析装置や分子診断検査などの検査プラットフォームの革新により、利用できる検査の幅が広がり、出血や凝固障害の根本的な原因をより正確に検出できるようになりました。

新興国における継続的な調査による出血性疾患に対する認識と理解の向上が、治療薬市場の成長を促進しています。公衆衛生キャンペーンや医学調査により、血友病、深部静脈血栓症 (DVT) 、肺塞栓症などの疾患の管理における早期診断と介入の重要性が強調されています。その結果、これらの疾患のリスクがある患者の定期的なスクリーニングとモニタリングが重視されるようになり、止血診断検査に対する需要が高まっています。

慢性疾患、特に心血管系に関連する疾患の有病率の上昇も市場の成長に寄与しています。心血管疾患は、動脈に血栓が形成されたり、脳卒中や心臓発作を予防するために抗凝固療法が行われたりすることで、しばしば凝固障害を引き起こします。慢性心血管系疾患と診断される人が増えるにつれ、血液凝固や出血のリスクをモニターできる診断検査のニーズが高まり、市場をさらに牽引しています。

さらに、個別化医療の普及が止血診断薬市場に一役買っています。止血に関して言えば、個別化医療は出血や血液凝固障害のリスクが高い患者を特定するのに役立ち、医療提供者が最も適切な診断検査や治療を選択できるようにします。この動向は、個々の患者の特定のニーズに対応できる、より的を絞った診断ツールの開発を促しています。

同市場の主要企業には、F. Hoffmann-La Roche AG、Danaher Corporation、Sysmex Corporation、Siemens Healthineers、Horiba Medical、Haemonetics Corporation、HemoSonics, LLC、Sterile Safequip and Chemicals LLP、TECO Medical Instruments、Stagoなどがあります。各社が選択した主な戦略には、より迅速で正確な結果を提供する、より高度な自動化されたポイントオブケア診断機器の導入など、製品開発におけるイノベーションが含まれます。また、病院、研究機関、その他の医療提供者との戦略的提携や協力関係も、市場へのリーチを拡大し、製品提供を強化する上で極めて重要です。さらに各社は、ルーチン検査と特殊検査の両方のニーズに対応するため、より広範な診断検査を含む製品ポートフォリオの拡充に注力しています。

止血診断薬市場：分析概要

• 製品別では、消耗品が2024年に61.1%と最大の売上シェアを占める。検査件数の増加に伴い、消耗品の需要は予測期間中に有利な成長を示す可能性が高いです。
• 検査別では、プロトロンビン時間検査が市場を独占し、2024年には31.5%の最大シェアを占めました。PT検査は、病院、診療所、さらにはポイントオブケアの場所など、さまざまな医療環境で実施できるため、タイムリーな診断と治療に利用しやすくなっています。さらに、この検査には比較的短い所要時間があるため、臨床医は患者のケアに関して迅速な決定を下すことができます。
• 最終用途別では、病院部門が2024年に57.7％の最大売上シェアで市場を独占しました。このセグメントの優位性は、病院で検査される患者数が多いことに起因しています。
• 北米は、確立された医療インフラにより、出血性疾患や凝固障害患者のタイムリーな診断と管理が可能であることから、世界市場を独占しました。
• アジア太平洋地域は、2025年から2030年までの予測期間においてCAGR 5.1％で最も速い成長を遂げると予想されます。これは新興国市場全体で医療施設が増加しているためです。さらに、予防的ルーチン検査への注目の高まりも市場の成長を支えています。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 止血診断薬市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• 止血診断薬市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析

第4章 止血診断薬市場：製品別の推定・動向分析

• 市場シェア：製品別 (2024年・2030年)
• セグメントダッシュボード
• 世界の止血診断薬市場の展望：製品別
• 市場規模の予測と動向分析 (2018～2030年)
  • ラボ用分析装置
  • ポイントオブケア検査システム
  • 消耗品

第5章 止血診断薬市場：検査別の推定・動向分析

• 市場シェア：検査別 (2024年・2030年)
• セグメントダッシュボード
• 世界の止血診断薬市場の展望：検査別
• 市場規模の予測と動向分析 (2018～2030年)
  • 活性化部分トロンボプラスチン時間
  • Dダイマー検査
  • フィブリノーゲン検査
  • プロトロンビン時間 (PT) 検査
  • その他のテスト

第6章 止血診断薬市場：最終用途別の推定・動向分析

• 市場シェア：最終用途別 (2024年・2030年)
• セグメントダッシュボード
• 世界の止血診断薬市場の展望：最終用途別
• 市場規模の予測と動向分析 (2018～2030年)
  • 病院
  • 診断検査室
  • その他

第7章 止血診断薬市場：地域別の推定・動向分析

• 市場シェア：地域別 (2024年・2030年)
• 地域別ダッシュボード
• 世界の止血診断薬市場の展望：地域別
• 市場規模の予測と動向分析 (2018～2030年)
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 最新動向と影響分析：主な市場参入企業別
• 企業/競合の分類
• ベンダー情勢
  • Key company market share analysis, 2024
  • F. Hoffmann-La Roche AG
  • Danaher Corporation
  • Sysmex Corporation
  • Siemens Healthineers
  • Horiba Medical
  • Haemonetics Corporation
  • HemoSonics, LLC
  • Sterile Safequip and Chemicals LLP
  • TECO Medical Instruments
  • Stago

List of Tables

• Table. 1 List of Abbreviation
• Table. 2 North America hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 3 North America hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 4 North America hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 5 U.S. hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 6 U.S. hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 7 U.S. hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 8 Canada hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 9 Canada hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 10 Canada hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 11 Mexico hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 12 Mexico hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 13 Mexico hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 14 Europe hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 15 Europe hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 16 Europe hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 17 UK hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 18 UK hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 19 UK hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 20 Germany hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 21 Germany hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 22 Germany hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 23 France hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 24 France hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 25 France hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 26 Italy hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 27 Italy hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 28 Italy hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 29 Spain hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 30 Spain hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 31 Spain hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 32 Denmark hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 33 Denmark hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 34 Denmark hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 35 Sweden hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 36 Sweden hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 37 Sweden hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 38 Norway hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 39 Norway hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 40 Norway hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 41 Asia Pacific hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 42 Asia Pacific hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 43 Asia Pacific hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 44 Japan hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 45 Japan hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 46 Japan hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 47 China hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 48 China hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 49 China hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 50 India hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 51 India hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 52 India hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 53 Australia hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 54 Australia hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 55 Australia hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 56 Thailand hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 57 Thailand hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 58 Thailand hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 59 South Korea hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 60 South Korea hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 61 South Korea hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 62 Latin America hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 63 Latin America hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 64 Latin America hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 65 Brazil hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 66 Brazil hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 67 Brazil hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 68 Argentina hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 69 Argentina hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 70 Argentina hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 71 Middle East & Africa hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 72 Middle East & Africa hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 73 Middle East & Africa hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 74 South Africa hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 75 South Africa hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 76 South Africa hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 77 Saudi Arabia hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 78 Saudi Arabia hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 79 Saudi Arabia hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 80 UAE hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 81 UAE hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 82 UAE hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table. 83 Kuwait hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
• Table. 84 Kuwait hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
• Table. 85 Kuwait hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Hemostasis Diagnostics: Market outlook
• Fig. 9 Hemostasis Diagnostics: Competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 Hemostasis Diagnostics Market driver impact
• Fig. 15 Hemostasis Diagnostics Market restraint impact
• Fig. 16 Hemostasis Diagnostics Market strategic initiatives analysis
• Fig. 17 Hemostasis Diagnostics market: Product movement analysis
• Fig. 18 Hemostasis Diagnostics market: Product outlook and key takeaways
• Fig. 19 Laboratory Analyzers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Point-of-Care Testing Systems market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 Consumables market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 Automated Systems market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 Semi-automated Systems market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 Manual Systems market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Hemostasis Diagnostics market: Test movement analysis
• Fig. 26 Hemostasis Diagnostics market: Test outlook and key takeaways
• Fig. 27 Activated Partial Thromboplastin Time market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 D-Dimer Test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Fibrinogen Test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Prothrombin Time (PT) Test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Other Tests market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Hemostasis Diagnostics market: End Use movement analysis
• Fig. 33 Hemostasis Diagnostics market: End Use outlook and key takeaways
• Fig. 34 Hospitals hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Diagnostic Laboratories hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Others hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 North America hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 U.S. hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Canada hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Mexico hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Europe hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 UK hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Germany hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 France hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Italy hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Spain hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Sweden hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Norway hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Denmark hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Asia Pacific hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Japan hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 China hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 India hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Australia hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Thailand hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 South Korea hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Latin America hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Brazil hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Argentina hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Middle East and Africa. hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Saudi Arabia hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 South Africa hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 UAE hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Kuwait hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)

Hemostasis Diagnostics Market Growth & Trends:

The global hemostasis diagnostics market size is expected to reach USD 1.49 billion by 2030, registering a CAGR of 4.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is likely to show significant growth due to various factors, such as the growing geriatric population across the globe, advancements in diagnostic technologies, increasing awareness of bleeding and clotting disorders, and the rising prevalence of chronic diseases.

One of the primary drivers of the market is the growing geriatric population. As people age, the likelihood of developing conditions that affect hemostasis, such as venous thromboembolism, atrial fibrillation, and other cardiovascular diseases, increases. Older individuals are also more likely to undergo surgeries that require accurate monitoring of coagulation levels to avoid complications like excessive bleeding or clot formation. This demographic trend is boosting the demand for diagnostic tools that can assess blood clotting and bleeding risks.

Technological advancements in terms of product development are also contributing to market growth. The development of sophisticated and accurate diagnostic analyzers, such as point-of-care devices, has made it easier for healthcare providers to quickly monitor coagulation parameters across various healthcare settings. These advancements have improved the speed and efficiency of diagnosing hemostasis disorders, which is particularly important in emergency and critical care settings.

In addition, innovations in testing platforms, such as automated analyzers and molecular diagnostic tests, have expanded the range of tests available, allowing for more precise detection of underlying causes of bleeding and clotting disorders.

Increased awareness and better understanding of bleeding disorders owing to continuous research in emerging economies are driving the growth of the hemostasis diagnostics market. Public health campaigns and medical research have highlighted the importance of early diagnosis and intervention in managing conditions such as hemophilia, deep vein thrombosis (DVT), and pulmonary embolism. As a result, there is a greater emphasis on regular screening and monitoring of patients at risk of these conditions, which increases the demand for hemostasis diagnostic tests.

The rising prevalence of chronic diseases, particularly those related to the cardiovascular system, is also contributing to the growth of the market. Cardiovascular diseases often lead to clotting disorders, either due to the formation of blood clots in the arteries or the use of anticoagulant therapies to prevent strokes and heart attacks. As more individuals are diagnosed with chronic cardiovascular conditions, there is an increased need for diagnostic tests that can monitor blood clotting and bleeding risks, further driving the market.

Furthermore, the growing adoption of personalized medicine is playing a role in the hemostasis diagnostics market. In the context of hemostasis, personalized medicine can help identify patients who are at higher risk of bleeding or clotting disorders, enabling healthcare providers to choose the most appropriate diagnostic tests and treatments. This trend is encouraging the development of more targeted diagnostic tools that can cater to the specific needs of individual patients.

Some key players in the market are F. Hoffmann-La Roche AG; Danaher Corporation; Sysmex Corporation; Siemens Healthineers; Horiba Medical; Haemonetics Corporation; HemoSonics, LLC; Sterile Safequip and Chemicals LLP; TECO Medical Instruments; Stago and more. Key strategies opted by the companies include innovation in product development, such as introducing more advanced, automated, and point-of-care diagnostic devices that offer faster, more accurate results. Strategic partnerships and collaborations with hospitals, research institutions, and other healthcare providers are also crucial for expanding market reach and enhancing product offerings. Additionally, companies are focusing on expanding their product portfolios to include a broader range of diagnostic tests, catering to both routine and specialized testing needs.

Hemostasis Diagnostics Market Report Highlights:

• Based on product, consumables accounted for the largest revenue share of 61.1% in 2024. With the increasing number of tests being performed, the demand for consumables is likely to show lucrative growth over the forecast period.
• Based on test, the prothrombin time test dominated the market and accounted for the largest share of 31.5% in 2024.The PT test can be performed in various healthcare settings, including hospitals, clinics, and even point-of-care locations, making it accessible for timely diagnosis and treatment. Additionally, the test has a relatively short turnaround time, allowing clinicians to make rapid decisions regarding patient care.
• Based on end use, the hospitals segment dominated the market with the largest revenue share of 57.7% in 2024. The segment dominance is attributed to large patient volumes being tested in hospitals.
• North America dominated the global market owing to well-established healthcare infrastructure allowing timely diagnosis and management of patients with bleeding and clotting disorders.
• The Asia Pacific region is expected to witness the fastest growth with a CAGR of 5.1% over the forecast period from 2025 to 2030, due to the development of healthcare facilities across emerging markets. Furthermore, increasing focus on preventive routine testing is also supporting the market growth.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Test
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Test outlook
  • 2.2.2. Product outlook
  • 2.2.3. End Use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Hemostasis Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Prevalence of Bleeding Disorders
    • 3.2.1.2. Technological Advancements
    • 3.2.1.3. Awareness of Preventive Healthcare
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Advanced Devices
    • 3.2.2.2. Lack of Skilled Personnel
• 3.3. Hemostasis Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Hemostasis Diagnostics Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Hemostasis Diagnostics Market by Product Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Laboratory Analyzers
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Automated Systems
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Semi-automated Systems
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.4. Manual Systems
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Point-of-Care Testing Systems
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Consumables
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Hemostasis Diagnostics Market: Test Estimates & Trend Analysis

• 5.1. Test Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Hemostasis Diagnostics Market by Test Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Activated Partial Thromboplastin Time
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. D-Dimer Test
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Fibrinogen Test
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Prothrombin Time (PT) Test
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. Other Tests
    • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Hemostasis Diagnostics Market: End Use Estimates & Trend Analysis

• 6.1. End Use Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Hemostasis Diagnostics Market by End Use Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Hospitals
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Diagnostic Laboratories
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Others
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Hemostasis Diagnostics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Target disease prevalence
    • 7.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Target disease prevalence
    • 7.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Target disease prevalence
    • 7.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Target disease prevalence
    • 7.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Target disease prevalence
    • 7.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Target disease prevalence
    • 7.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Target disease prevalence
    • 7.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Target disease prevalence
    • 7.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Target disease prevalence
    • 7.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Target disease prevalence
    • 7.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Target disease prevalence
    • 7.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Target disease prevalence
    • 7.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Target disease prevalence
    • 7.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. Target disease prevalence
    • 7.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Target disease prevalence
    • 7.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. Target disease prevalence
    • 7.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Target disease prevalence
    • 7.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Target disease prevalence
    • 7.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Target disease prevalence
    • 7.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. Target disease prevalence
    • 7.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Target disease prevalence
    • 7.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. Target disease prevalence
    • 7.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Target disease prevalence
    • 7.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company market share analysis, 2024
  • 8.3.2. F. Hoffmann-La Roche AG
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Danaher Corporation
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Sysmex Corporation
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Siemens Healthineers
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Horiba Medical
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Haemonetics Corporation
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. HemoSonics, LLC
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Sterile Safequip and Chemicals LLP
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. TECO Medical Instruments
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Stago
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives